| Author (Corporate) | European Medicines Agency |
|---|---|
| Series Title | Press Release |
| Series Details | EMA/585784/2010 (23.9.10) |
| Publication Date | 23/09/2010 |
| Content Type | News |
|
The European Medicines Agency (EMA), on 23 September 2010, recommended the suspension of the marketing authorisations for the rosiglitazone-containing anti-diabetes medicines Avandia, Avandamet and Avaglim. These medicines will stop being available in Europe within the next few months. |
|
| Source Link | Link to Main Source http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2010/09/news_detail_001119.jsp&mid=WC0b01ac058004d5c1&murl=menus/news_and_events/news_and_events.jsp |
| Related Links |
|
| Subject Categories | Health |
| Countries / Regions | Europe |
